Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AT-533 是有效的 HSV 和 Hsp90 抑制剂。AT-533 可以阻断 HIF-1α/VEGF/VEGFR-2 信号通路,从而抑制血管生成和肿瘤生长。AT-533 也抑制下游通路的激活,包括 Erk1/2, FAK, Akt/mTOR/p70S6K。AT-533 抑制人脐静脉内皮细胞 (HUVEC) 的细胞迁移、侵袭和管形成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 928 | 现货 | ||
5 mg | ¥ 2,280 | 现货 | ||
10 mg | ¥ 3,670 | 现货 | ||
25 mg | ¥ 5,930 | 现货 | ||
50 mg | ¥ 8,220 | 现货 | ||
100 mg | ¥ 10,800 | 现货 | ||
500 mg | ¥ 21,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,510 | 现货 |
产品描述 | AT-533 is a potent inhibitor of Hsp90 and HSV. AT-533 blocks the HIF-1α/VEGF/VEGFR-2 signaling pathway, leading to suppress tumor growth and angiogenesis. AT-533 also inhibits the activation of the downstream pathways, including Erk1/2, FAK, Akt/mTOR/p70S6K,. AT-533 inhibits the cell migration, invasion, and the tube formation of human umbilical vein endothelial cells (HUVECs). |
体外活性 | AT-533 (0-1350 nM; 24h or 48h) inhibits 20ng/mL VEGF induced tube formation, cell migration and HUVEC invasion. AT-533 (2 μ M or 75 μ M; 24 h) inhibits HIF-1 α/ VEGF in hypoxia induced breast cancer cells signaling pathway and inhibits Akt/mTOR/p70S6K, Erk1/2, and FAK phosphorylation. AT-533 (10 nM, 50 nM; 48 h) exhibits anti angiogenic ability on the chorionic villus (CAM) model [1]. AT-533 (0.5 μ M; 2 hours, 4 hours) reduces TNF induced by HSV-1 in RAW264.7 and BV2 cells- α、 IL-1 β and the production of IL-6 [2]. |
体内活性 | AT-533 (10 mg/kg; intraperitoneal injection; once a day for 21 days) inhibited the expression of HIF-1 α/ VEGF signaling pathway related proteins in mouse MDA-MB-231 xenograft model of breast cancer [1]. AT-533 (1, 2, 4 mg/kg; intraperitoneal injection; once a day for 30 days) did not cause death, appetite loss, weight loss, or adverse reactions in subacute toxicity tests of Sprague Dawley rats [3]. |
分子量 | 410.51 |
分子式 | C23H30N4O3 |
CAS No. | 908112-37-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30.0 mg/mL (73.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.436 mL | 12.18 mL | 24.3599 mL | 60.8999 mL |
5 mM | 0.4872 mL | 2.436 mL | 4.872 mL | 12.18 mL | |
10 mM | 0.2436 mL | 1.218 mL | 2.436 mL | 6.09 mL | |
20 mM | 0.1218 mL | 0.609 mL | 1.218 mL | 3.045 mL | |
50 mM | 0.0487 mL | 0.2436 mL | 0.4872 mL | 1.218 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AT-533 908112-37-8 Cytoskeletal Signaling Metabolism Microbiology/Virology HSP HSV AT 533 AT533 Benzamide,2[(trans4hydroxycyclohexyl)amino]4(4,5,6,7tetrahydro3,6,6trimethyl4oxo1Hindazol1yl) Inhibitor inhibitor inhibit